Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
about
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonistLipid-lowering efficacy of atorvastatinUnmet Needs in LDL-C Lowering: When Statins Won't Do!CETP Inhibition: Past Failures and Future HopesStructural Insights into High Density Lipoprotein: Old Models and New FactsCurrent therapies for lowering lipoprotein (a)New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugsResidual macrovascular risk in 2013: what have we learned?Regression of atherosclerosis: insights from animal and clinical studiesInsights into the Tunnel Mechanism of Cholesteryl Ester Transfer Protein through All-atom Molecular Dynamics SimulationsCrystal Structures of Cholesteryl Ester Transfer Protein in Complex with InhibitorsZebrafish Models for Dyslipidemia and Atherosclerosis ResearchStatin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementLowering cholesterol in chronic kidney disease: is it safe and effective?Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilNiacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulationsLDL-Cholesterol: Standards of Treatment 2016: A German Perspective.Lipid Lowering Therapy to Modify Plaque Microstructures.Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitmEffects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and EPharmacological postconditioning with atorvastatin calcium attenuates myocardial ischemia/reperfusion injury in diabetic rats by phosphorylating GSK3β.CETP inhibitors and cardiovascular disease: Time to think again.Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.Pharmacogenetics in clinical practice: how far have we come and where are we going?Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical OutcomesTolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.HDL and cognition in neurodegenerative disorders.Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adultsAnacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.Evolving targets for lipid-modifying therapyHigh-density lipoproteins and coronary artery disease: a single-center cohort study.Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State.Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.Treatment Options for Statin-Associated Muscle Symptoms.Emerging roles for cholesterol and lipoproteins in lung disease.Targeting high density lipoproteins in the prevention of cardiovascular disease?Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO.
P2860
Q21132391-2A07946D-B7C7-441A-8F03-22784A245469Q24187301-532DFDE8-AA3D-45DB-9E22-F1BC046FF03DQ26741705-9A3BF37C-C595-4BAF-B2D0-E26CCCB24B67Q26753158-340EA6E9-A2F8-40E6-BA1C-BC47FA55AF69Q26770434-A01DFB7E-A041-4ACE-B51C-DA8E97749602Q26830297-225562DD-CF0C-4666-A8B5-BD985BB6285CQ26863369-6D7F9AB8-4D7C-42CC-A52C-12D88328F314Q26996039-5C7975D1-1373-4663-8A25-4EBDDB8A491CQ27028112-0CA9B215-E125-416C-A456-02123122757EQ27312096-53FF8869-7C95-4B80-8E5C-E0EEE313FF83Q27672820-7CD782D1-9403-46E4-BA7D-6C36F3D61D61Q28069803-6AE3EEB5-02F8-49D0-9A0F-4C87BB037FDEQ28083004-B23853F1-68C7-4DDE-8C33-E47F42012F2BQ28083502-7F77119E-AFD7-4C9E-81AD-636FE7FCC36EQ28084156-BAF08E0E-4FE8-4B94-8F69-E7F77B2A9316Q28086787-6E641FF0-2EB1-4E53-B8E2-6E2F377CC983Q28545075-D5C8AB77-916C-44BD-BFC0-1154BF01B2D7Q30248925-A736CA88-5F2B-4F73-9955-686E87B0C6DEQ33567290-72182D91-A600-41DB-AF24-A8E9F69ED498Q33643426-F4CAC1E8-CC55-4D34-86F3-9B5BFB38EFF9Q33754249-662A8157-DF07-4151-9C6B-3B54AC6D4DD6Q33846404-17B60167-63B7-4353-BFC3-75B71B7D3E1BQ34109100-62FDBA28-488B-4817-B0BA-E0FF2AFAE489Q34253290-2875BAE8-BBA0-4D43-A238-79D46BAA3C36Q34343365-AA39A68C-4FF4-4988-8796-C2C0229B9A22Q34441411-364CB426-655A-4508-A515-4FEF68D3A84AQ34534212-74E4BB40-CF12-4F11-A98A-5C6B4D688721Q34571030-6ED19050-8617-40A2-BF8B-14C40EEB700EQ34614842-8C312048-DABA-4F34-B10E-CE7ABD88BB24Q34823459-87005F61-68E1-4588-87B0-9E8876C8C210Q34858025-71B72EE1-2E3B-40E9-9DCE-566BAC4E4495Q34880292-C28CFCA8-9592-431B-A5A1-64B4DAA9E934Q34992719-FD021F5F-FA2C-4DCF-A8A1-1CE484D994B2Q35034986-8C3633F0-612C-47CE-9437-C029736110D4Q35953512-1CFB28CF-3B79-4C75-AD69-7DBA349297AAQ36197815-FE4628EA-3179-4D35-9183-C0CC242AABCCQ36294394-455C4F40-5D14-44DD-A1A7-E45E7CC0413EQ36303634-2DD15B21-D84C-4322-A399-096F349AA405Q36453173-E33AEE90-E755-4D87-80DE-F848985D07ECQ36553833-2923594B-2F61-48DD-A46B-D10E9A096B66
P2860
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Effects of the CETP inhibitor ...... a randomized controlled trial.
@en
type
label
Effects of the CETP inhibitor ...... a randomized controlled trial.
@en
prefLabel
Effects of the CETP inhibitor ...... a randomized controlled trial.
@en
P2093
P356
P1476
Effects of the CETP inhibitor ...... a randomized controlled trial
@en
P2093
Ellen McErlean
H Bryan Brewer
John J P Kastelein
Kathryn A Krueger
Ming-Dauh Wang
Mingyuan Shao
Steven E Nissen
P304
P356
10.1001/JAMA.2011.1649
P407
P577
2011-11-01T00:00:00Z